- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04517747
Ramucirumab Plus TAS-102 in Patients With Advanced or Metastatic Gastric Adenocarcinoma or the Gastroesophageal Junction (RE-ExPEL)
A Pilot Study of Ramucirumab Beyond Progression Plus TAS-102 in Patients With Advanced or Metastatic Adenocarcinoma of the Stomach or the Gastroesophageal Junction, After Treatment Failure on a Ramucirumab Based Therapy
Study Overview
Status
Intervention / Treatment
Detailed Description
This is an interventional, prospective, non-randomized, open-label, multicenter single-arm pilot study of ramucirumab plus TAS-102 in patients with advanced or metastatic adenocarcinoma of the stomach or the gastroesophageal junction, after treatment failure on a ramucirumab based therapy.
A total number of 20 patients will be enrolled. Potential study participants will be assessed for eligibility during one or several screening visits. The patient has to provide a signed informed consent form prior to any study-specific screening evaluations. Once the patient provides a signed informed consent form and eligibility is confirmed (all inclusion/exclusion criteria have been verified), the patient can be enrolled.
All screening procedures must be completed during the 14-day screening period. All patients must have had disease status confirmed as per CT or MRI scan of the tumor(s) within ≤ 4 weeks prior to the first dose. Other screening assessments include blood sampling, performance status (ECOG) and ECG according to clinical routine. Study treatment will be continued until progression or intolerable toxicity, but for a maximum of 4 months. Further treatment after progression will be at the investigator's discretion.
Tumor assessment will be performed according to clinical routine at screening and every 8 weeks (±7 days) during the treatment phase of the study and every 12 weeks (±14 days) during follow-up.
The expected duration of the active study phase (FPI - LPO) is 18 months. The active phase per individual patient is approximately 6 months.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Frankfurt, Germany, 60488
- Institute for Clinical Cancer Research Krankenhaus Nordwest
-
Hamburg, Germany, 20246
- Hamburg Hämatologisch-Onkologische Praxis Eppendorf-Facharztzentrum Eppendorf
-
Mannheim, Germany, 68167
- Tagestherapiezentrum am ITM Universitätsmedizin Mannheim
-
Muenchen, Germany, 81675
- Technische Universität München Klinikum rechts der Isar
-
Ulm, Germany, 89081
- Universitätsklinikum Ulm
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Signed informed consent form.
Men or women* ≥ 18 years of age. Patients of reproductive age must be prepared to use a suitable contraceptive method during the study and up to 6 months after the end of treatment. A suitable method of contraception is defined as surgical sterilization (e.g. bilateral fallopian tube ligation, vasectomy), hormonal contraception (implantable, patch, oral), and double barrier methods (each two-fold combination of intrauterine pessary, condom for men, or women with spermicidal gel, diaphragm, contraceptive sponge, cervical cap). Women of child-bearing potential must have a negative pregnancy test within the last 7 days prior to the start of study therapy.
*There is no data that indicates a specific gender distribution. Therefore, patients are included regardless of their gender.
- Histologically proven adenocarcinoma of the stomach, including adenocarcinoma of the gastroesophageal junction (note: previous histological assessment during disease history of patient sufficient, current biopsy during screening for this trial is not mandatory)
- Documented, objective, radiological or clinical progression of the disease during or within 4-6 weeks after the last dose of a ramucirumab based second-line therapy (ramucirumab monotherapy or a combination of ramucirumab + paclitaxel, respectively ramucirumab + FOLFIRI).
- Measurable or non-measurable but evaluable disease.
- ECOG Performance status 0-2.
- Life expectancy > 8 weeks.
Appropriate haematological, hepatic and renal function:
- Absolute number of neutrophils (ANC) ≥ 1.5 x 10^9/L
- Platelets ≥ 100 x 10^9/L
- Hemoglobin ≥ 9 g/dL (5.58 mmol/L)
- Total bilirubin ≤ 1.5 times the upper limit of normal (UNL)
- AST (SGOT) and ALT (SGPT) ≤ 2.5 x UNL without existing liver metastases, or ≤ 5 x UNL in the presence of liver metastases; AP ≤ 5 x UNL
- Serum creatinine ≤ 1.5 x UNL or creatinine clearance (measured by 24h urine) ≥ 40 mL / min (i.e. if the serum creatinine level is > 1.5 x UNL, then a 24h urine test must be performed to check the creatinine clearance to be determined). Protein level in urine ≤ 1+ by dipstick analysis or routine urine measurement (if the dipstick analysis or the routine test ≥ 2+, a subsequent 24h urine protein measurement must show a value of < 1000mg of protein within 24h of participation to ensure the study.
- Adequate coagulability, as determined by the International Normalized Ratio (INR) ≤ 1.5 and partial thromboplastin time (PTT) ≤ 5 seconds above the UNL (unless anti-coagulation therapy has been given). Patients receiving warfarin / phenoprocoumon must be switched to low molecular weight heparin and must have a stable coagulation profile before starting study-specific therapy.
- Subject is willing and able to comply with the protocol (including contraceptive measures) for the duration of the study including undergoing treatment and scheduled visits and examinations including follow up.
Exclusion Criteria:
- Presence of tumors other than adenocarcinomas (e.g., leiomyosarcoma, lymphoma) or a secondary tumor other than squamous or basal cell carcinomas of the skin or in situ carcinomas of the cervix which have been effectively treated. The sponsor decides to include patients who have received curative treatment and have been disease-free for at least 5 years.
- Squamous cell carcinoma of the stomach or gastroesophageal junction.
- Simultaneous, ongoing, systemic immunotherapy, chemotherapy, or hormone therapy not described in the study protocol.
- Simultaneous treatment with a different anti-cancer therapy other than that provided for in the study (excluding palliative radiotherapy for symptom control).
- The patient is receiving chronic antiplatelet therapy, including aspirin, nonsteroidal anti-inflammatory drugs (NSAIDs, including ibuprofen, naproxen, and others), dipyridamole or clopidogrel, or similar agents. Once-daily aspirin use (maximum dose 325 mg/day) is permitted
- The patient has undergone major surgery within the last 28 days prior to the start of study-specific therapy or has undergone minor surgery within the last 7 days prior to the start of study therapy. The patient had subcutaneous venous access within the last 7 days prior to the start of the study-specific therapy. The patient plans to undergo major surgery while participating in the clinical trial.
- Gastrointestinal bleeding grade 3-4 within the last 3 months prior to enrollment in the study.
- History of deep vein thrombosis (DVT), pulmonary embolism (PE), or any other clinically important thromboembolic event during the last 3 months prior to the start of study-specific therapy (thrombosis caused by venous ports, catheters, or superficial venous thrombosis are not considered "clinically meaningful").
- Stage B cirrhosis according to Child-Pugh criteria (or worse) or cirrhosis (of any grade) with a history of hepatic encephalopathy or clinically significant ascites resulting from cirrhosis. Clinically significant ascites is defined as ascites resulting from cirrhosis requiring diuretics or paracentesis.
- Known brain or leptomeningeal metastases.
- Known allergic / hypersensitive reactions to at least one of the treatment components.
- Other serious illnesses or medical ailments within the last 12 months prior to the start of the study.
- Any arterial thromboembolic event which includes, but is not limited to, the following: myocardial infarction, transient ischemic attack, cerebrovascular insult, unstable angina within the last 6 months prior to the initiation of study therapy.
- Uncontrolled or under-adjusted hypertension (> 160 mmHg systolic or > 100 mmHg diastolic hypertension for more than 4 weeks) despite standard medical treatment.
- Presence of an active, uncontrollable infection.
- Chronic inflammatory bowel disease.
- Active disseminated intravascular coagulation.
- Any other serious concomitant or medical condition that, in the opinion of the investigator, presents a high risk of complications to the patient or reduces the likelihood of clinical effect.
- Known dihydropyrimidine dehydrogenase (DPD) deficiency.
- History of gastrointestinal perforation / fistula (within the last 6 months prior to the start of study-specific therapy) or presence of risk factors favoring perforation.
- Serious or non-healing wounds, ulcers, or broken bones within the last 28 days prior to the start of study-specific therapy.
- The patient is pregnant or breast-feeding.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Ramucirumab plus TAS-102
Ramucirumab 8 mg/kg i.v. on day 1 and day 15 of a 28-day cycle and TAS-102 35 mg/m2/dose p.o. twice daily on days 1 to 5 and days 8 to 12 of a 28-day cycle Each cycle will be repeated after 28 days (from day 1) for a maximum of 4 cycles.
|
chemotherapy i.v.
Other Names:
p.o. twice daily
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Tolerability and toxicity: rate of serious adverse events (SAEs) of any cause
Time Frame: Frist Treatment until 30 days after end of treatment, up to 5 months
|
The primary endpoint of the study is tolerability and toxicity, defined by the rate of serious adverse events (SAEs) of any cause according to CTCAE v5.0
|
Frist Treatment until 30 days after end of treatment, up to 5 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Rate of treatment-related AEs and SAE
Time Frame: Frist Treatment until 30 days after end of treatment, up to 5 months
|
Rate of treatment-related AEs and SAEs according to CTCAE v5.0
|
Frist Treatment until 30 days after end of treatment, up to 5 months
|
Adverse events for neutropenia
Time Frame: Frist Treatment until 30 days after end of treatment, up to 5 months
|
Rate of grade 3 or worse adverse events for neutropenia
|
Frist Treatment until 30 days after end of treatment, up to 5 months
|
Adverse events for anemia
Time Frame: Frist Treatment until 30 days after end of treatment, up to 5 months
|
Rate of grade 3 or worse adverse events for anemia
|
Frist Treatment until 30 days after end of treatment, up to 5 months
|
Adverse events for leucopenia
Time Frame: Frist Treatment until 30 days after end of treatment, up to 5 months
|
Rate of grade 3 or worse adverse events for leucopenia
|
Frist Treatment until 30 days after end of treatment, up to 5 months
|
Adverse events for thrombocytopenia
Time Frame: Frist Treatment until 30 days after end of treatment, up to 5 months
|
Rate of grade 3 or worse adverse events for thrombocytopenia
|
Frist Treatment until 30 days after end of treatment, up to 5 months
|
Abnormal laboratory parameters
Time Frame: Frist Treatment until 30 days after end of treatment, up to 5 months
|
Frequency of abnormal laboratory parameters
|
Frist Treatment until 30 days after end of treatment, up to 5 months
|
Progression Free Survival (PFS)
Time Frame: Progression free survival (PFS) is defined as the time from enrollment to the first documented evidence of disease progression or death; up to 16 months.
|
Progression Free Survival (PFS) according to RECIST 1.1, Progression free survival (PFS) is defined as the time from enrollment to the first documented evidence of disease progression or death.
If no information will be available for the evaluation of progression, patients will be censored at the timepoint of last tumor assessment.
|
Progression free survival (PFS) is defined as the time from enrollment to the first documented evidence of disease progression or death; up to 16 months.
|
Objective Response Rate (ORR)
Time Frame: defined as the time from enrollment up to 16 months.
|
Objective response rate is defined as proportion of patients with a best overall response of complete response (CR) or partial response (PR).
Tumor response will be evaluated using RECIST 1.1 criteria.
|
defined as the time from enrollment up to 16 months.
|
Overall survival
Time Frame: Overall survival (OS) is defined as the time from enrollment to the date of death from any cause.; up to 16 months.
|
Overall survival
|
Overall survival (OS) is defined as the time from enrollment to the date of death from any cause.; up to 16 months.
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- RE-ExPEL
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Gastric Adenocarcinoma
-
Memorial Sloan Kettering Cancer CenterRecruitingMetastatic Gastric Adenocarcinoma | Metastatic Gastroesophageal Junction Adenocarcinoma | Unresectable Gastric Adenocarcinoma | Unresectable Gastroesophageal Junction Adenocarcinoma | Metastatic Gastric Cancer | Unresectable Esophageal Cancer | Metastatic Esophageal Carcinoma | Metastatic Gastric... and other conditionsUnited States
-
National Cancer Institute (NCI)CompletedRecurrent Gastric Carcinoma | Adenocarcinoma of the Gastroesophageal Junction | Diffuse Gastric Adenocarcinoma | Gastric Intestinal Type Adenocarcinoma | Gastric Mixed AdenocarcinomaUnited States, Canada
-
City of Hope Medical CenterActive, not recruitingAdenocarcinoma of the Gastroesophageal Junction | Stage IV Gastric Cancer | Recurrent Gastric Cancer | Diffuse Adenocarcinoma of the Stomach | Intestinal Adenocarcinoma of the Stomach | Mixed Adenocarcinoma of the Stomach | Stage IIIA Gastric Cancer | Stage IIIB Gastric Cancer | Stage IIIC Gastric Cancer and other conditionsUnited States
-
University of ChicagoNational Cancer Institute (NCI)RecruitingGastric Adenocarcinoma | Esophageal Adenocarcinoma | Stage IIIA Gastric Cancer | Stage IIIB Gastric Cancer | Stage IIIC Gastric Cancer | Stage IIB Gastric Cancer | Stage IIIA Esophageal Adenocarcinoma | Stage IIIB Esophageal Adenocarcinoma | Stage IIIC Esophageal AdenocarcinomaUnited States
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)RecruitingClinical Stage III Gastric Cancer AJCC v8 | Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8 | Clinical Stage IV Gastric Cancer AJCC v8 | Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8 | Metastatic Gastric Adenocarcinoma | Metastatic Gastroesophageal Junction... and other conditionsUnited States, Puerto Rico
-
H. Lee Moffitt Cancer Center and Research InstituteActive, not recruitingGastric Cancer | Gastric Adenocarcinoma | Gastroesophageal Junction AdenocarcinomaUnited States
-
Ukrainian Society of Clinical OncologyRecruitingStomach Cancer | Gastric Cancer | Gastric Adenocarcinoma | Gastrointestinal Cancer | Gastroesophageal Junction Adenocarcinoma | Advanced Gastric Adenocarcinoma | GastroEsophageal Cancer | Stomach Neoplasm | Gastric Neoplasm | Advanced Gastric Carcinoma | Advanced Gastroesophageal Junction AdenocarcinomaUkraine
-
M.D. Anderson Cancer CenterRecruitingClinical Stage III Gastric Cancer AJCC v8 | Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8 | Clinical Stage IV Gastric Cancer AJCC v8 | Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8 | Metastatic Gastric Adenocarcinoma | Metastatic Gastroesophageal Junction... and other conditionsUnited States
-
National Cancer Institute (NCI)Not yet recruitingClinical Stage III Gastric Cancer AJCC v8 | Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8 | Clinical Stage IV Gastric Cancer AJCC v8 | Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8 | Metastatic Gastric Adenocarcinoma | Metastatic Gastroesophageal Junction... and other conditions
-
National Cancer Institute (NCI)CompletedAdenocarcinoma of the Gastroesophageal Junction | Stage IV Gastric Cancer | Recurrent Gastric Cancer | Diffuse Adenocarcinoma of the Stomach | Intestinal Adenocarcinoma of the Stomach | Mixed Adenocarcinoma of the Stomach | Stage IIIA Gastric Cancer | Stage IIIB Gastric Cancer | Stage IIIC Gastric CancerUnited States
Clinical Trials on Ramucirumab
-
Shanghai Henlius BiotechTerminatedHealthy Male VolunteersChina
-
Yonsei UniversityNot yet recruiting
-
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.CompletedGastric Cancer | Non-small Cell Lung Cancer | Colo-rectal CancerChina
-
Eli Lilly and CompanyParexelCompleted
-
Eli Lilly and CompanyCompleted
-
Yale UniversityWithdrawnTransitional Cell CarcinomaUnited States
-
Eli Lilly and CompanyCompleted
-
Samsung Medical CenterRecruiting
-
Eli Lilly and CompanyCompletedHepatocellular CarcinomaUnited States, Canada, Belgium, Germany, Israel, Korea, Republic of, Spain, Australia, Austria, Brazil, France, Italy, Japan, Portugal, Taiwan, Romania, Bulgaria, Czech Republic, Finland, Hong Kong, Hungary, Netherlands, Norway, Phili... and more
-
Sidney Kimmel Comprehensive Cancer Center at Johns...National Cancer Institute (NCI); Eli Lilly and CompanyCompletedAdult Glioblastoma MultiformeUnited States